Lisa Belfiore
Overview
Explore the profile of Lisa Belfiore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yee C, Chan Y, Utama R, Besnier M, Engel M, Belfiore L
STAR Protoc
. 2024 Aug;
5(3):103234.
PMID: 39128008
To improve human hepatotoxicity prediction, in vitro liver cell models replicating hepatocyte function, drug metabolism, and toxicity are required. Here, we present a protocol for creating 3D primary human hepatocyte...
2.
Engel M, Belfiore L, Aghaei B, Sutija M
SLAS Technol
. 2022 Jan;
27(1):32-38.
PMID: 35058203
Advanced three dimensional cell culture techniques have been adopted in many laboratories to better model in vivo tissue by recapitulating multi-cellular architecture and the presence of extracellular matrix features. We...
3.
Belfiore L, Aghaei B, Law A, Dobrowolski J, Raftery L, Tjandra A, et al.
Eur J Pharm Sci
. 2021 May;
163:105876.
PMID: 33989755
Successful preclinical drug testing relies in part on data generated using in vitro cell culture models that recapitulate the structure and function of tumours and other tissues in vivo. The...
4.
Belfiore L, Saunders D, Ranson M, Vine K
Pharmaceutics
. 2020 Jul;
12(7).
PMID: 32645963
The urokinase plasminogen activator and its receptor (uPA/uPAR) are biomarkers for metastasis, especially in triple-negative breast cancer. We prepared anti-mitotic -alkylisatin (-AI)-loaded liposomes functionalized with the uPA/uPAR targeting ligand, plasminogen...
5.
Geraghty N, Belfiore L, Adhikary S, Alexander S, Sluyter R, Watson D
Transpl Immunol
. 2019 Feb;
54:38-46.
PMID: 30743002
Graft-versus-host disease (GVHD) is a frequent complication following allogeneic hematopoietic stem cell transplantation (HSCT) with current therapies limited to general immunosuppression. Humanized mouse models of GVHD are emerging as valuable...
6.
Belfiore L, Spenkelink L, Ranson M, van Oijen A, Vine K
J Control Release
. 2018 Mar;
278:80-86.
PMID: 29577949
Despite the longstanding existence of liposome technology in drug delivery applications, there have been no ligand-directed liposome formulations approved for clinical use to date. This lack of translation is due...
7.
Belfiore L, Saunders D, Ranson M, Thurecht K, Storm G, Vine K
J Control Release
. 2018 Mar;
277:1-13.
PMID: 29501721
The development of therapeutic resistance to targeted anticancer therapies remains a significant clinical problem, with intratumoral heterogeneity playing a key role. In this context, improving the therapeutic outcome through simultaneous...
8.
Bommer U, Vine K, Puri P, Engel M, Belfiore L, Fildes K, et al.
Cell Commun Signal
. 2017 Feb;
15(1):9.
PMID: 28143584
Background: Translationally controlled tumour protein TCTP is an anti-apoptotic protein frequently overexpressed in cancers, where high levels are often associated with poor patient outcome. TCTP may be involved in protecting...
9.
Vine K, Belfiore L, Jones L, Locke J, Wade S, Minaei E, et al.
Heliyon
. 2016 Jul;
2(1):e00060.
PMID: 27441242
The search for novel anticancer therapeutics with the ability to overcome multi-drug resistance (MDR) mechanisms is of high priority. A class of molecules that show potential in overcoming MDR are...